Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Anika Therapeutics (ANIK) over the last 11 years, with Q3 2025 value amounting to $14.4 million.

  • Anika Therapeutics' Shares Outstanding (Diluted Average) fell 236.98% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 236.98%. This contributed to the annual value of $15.4 million for FY2015, which is 49.09% up from last year.
  • Anika Therapeutics' Shares Outstanding (Diluted Average) amounted to $14.4 million in Q3 2025, which was down 236.98% from $14.3 million recorded in Q1 2025.
  • Over the past 5 years, Anika Therapeutics' Shares Outstanding (Diluted Average) peaked at $14.8 million during Q2 2024, and registered a low of $14.3 million during Q1 2025.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $14.7 million (2023), whereas its average is $14.6 million.
  • As far as peak fluctuations go, Anika Therapeutics' Shares Outstanding (Diluted Average) surged by 129.27% in 2023, and later plummeted by 272.83% in 2025.
  • Over the past 4 years, Anika Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $14.6 million in 2022, then increased by 0.38% to $14.7 million in 2023, then rose by 0.75% to $14.8 million in 2024, then dropped by 2.37% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, $14.3 million for Q1 2025, and $14.8 million during Q3 2024.